Short-term radiotherapy followed by chemotherapy for advanced rectal cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This multicenter, open-label phase II clinical study aims to evaluate the complete response rate in patients with RAS/BRAF wild type locally advanced rectal cancer (LARC) treated with a combination of short-term radiotherapy, HLX07, Serplulimab, and CAPOX. The study includes 29 patients and focuses on assessing both pathological and clinical complete responses through various evaluation methods, including digital rectal examination and MRI. The primary endpoint is the complete response rate, defined as the absence of viable tumor cells in resected specimens and lymph nodes.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Patients or their family members agree to participate in the study and sign the informed consent form;
2. Age 18-75 years, male or female;
3. Histologically confirmed Locally Advanced rectal adenocarcinoma
4. Genetic test and/or immunohistochemical confirmation of RAS, BRAF wild type
5. inferior margin ≤ 10 cm from the anal verge;
6. Pelvic MRI shows high risk \[meets one of the following conditions\]:

   * Clinical tumor (cT) staging cT4a or cT4b (according to AJCC 8th Edition)
   * Extramural vascular infiltration
   * Clinical lymph node (cN) staging cN2 (according to AJCC 8th Edition)
   * Mesenteric fascia is involved
   * Lateral lymph node enlargement 7 ECOG performance status score is 0-1;

8\. Swallowing pills normally; 9. Untreated with anti-tumor therapy for rectal cancer, including radiotherapy, chemotherapy, surgery, etc; 10. There was no operative contraindication; 11. Laboratory tests were required to meet the following requirements: white blood cell (WBC) ≥ 4×109/L; Absolute neutrophil count (ANC) ≥ 1.5×109/L; Platelet count ≥ 100×109/L; Hemoglobin ≥90 g/L; Serum total bilirubin ≤ 1.5 × upper limit of normal (ULN); Serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.5 × ULN; Serum creatinine ≤1.5 times the upper limit of normal value or creatinine clearance rate ≥50 mL/min; International normalized ratio (INR) ≤ 1.5 × ULN; Activated partial thromboplastin time (APTT) ≤ 1.5 × ULN 12. Males or females with reproductive ability who are willing to use contraception in the trial;

Exclusion Criteria:

1. Documented history of allergy to study drugs, including any component of Anti-EGFR or PD-1 antibody, capecitabine, oxaliplatin and other platinum drugs;
2. Have received or are receiving any of the following treatments:

   Any radiotherapy, chemotherapy or other anti-tumor drugs for tumor; Patients who need to be treated with corticosteroid (dose equivalent to prednisone of \>10 mg/day) or other immunosuppressive agents within 2 weeks prior to study drug administration; Received live attenuated vaccine within 4 weeks before the first use of the study drug; Major surgery or severe trauma within 4 weeks before the first use of the study drug;
3. Any active autoimmune disease or history of autoimmune disease;
4. Have a history of immunodeficiency, including HIV positive, or other acquired or congenital immunodeficiency diseases, or have a history of organ transplantation or allogeneic bone marrow transplantation;
5. There are clinical symptoms or diseases of heart that are not well controlled;
6. Severe infection (CTCAE \> 2) occurred within 4 weeks before the first use of the study drug; Baseline chest imaging revealed active pulmonary inflammation, signs and symptoms of infection within 14 days prior to the first use of the study drug, or oral or intravenous antibiotic therapy, except for prophylactic use of antibiotics;
7. Patients with active pulmonary tuberculosis infection found by medical history or CT examination, or with a history of active pulmonary tuberculosis infection within one year before enrollment, or with a history of active pulmonary tuberculosis infection more than one year ago but without regular treatment;
8. The presence of active hepatitis B (HBV DNA \> 2000 IU/mL or 104 copies/mL) was positive for hepatitis C (hepatitis C antibody) and HCV RNA was higher than the lower limit of analytical method;
9. Female subject who is pregnant or breastfeeding;
10. Patients who are not suitable for participation in clinical trials in the opinion of the investigator

Where it's running

• Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
  Wuhan, Hubei, China Recruiting
• Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
  Wuhan, Hubei, China Recruiting
• Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
  Hubei, China Recruiting

Study contacts

• Principal investigator: Zhenyu Lin, MD — Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
• Study coordinator: zhenyu Lin, MD
• Email: whxhlzy@hust.edu.cn
• Phone: 027-85871982

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Single vs. double stapling and purse-string techniques after rectal cancer surgery

  This trial tests whether using a single-stapling method to join the bowel after rectal cancer surgery results in fewer leaks compared with the double-stapling method.

  Recruiting Alexandria University · Alexandria · NCT07929415

• NeoCSR-Omics: CAPOX and Serplulimab Before or After Short-Course RT in Locally Advanced Rectal Cancer

  This trial tests whether giving CAPOX chemotherapy with the PD-1 blocker serplulimab before or after short-course radiotherapy helps people with locally advanced rectal cancer achieve complete clinical or pathological responses.

  Recruiting Phase 2 Chongqing University Cancer Hospital · Chongqing, Chongqing Municipality · NCT07898865

• DEM301 in advanced colorectal cancer: a first-in-human test

  This first-in-human Phase 1 study tests DEM301 in adults with advanced metastatic colorectal cancer to see if it is safe, how it behaves in the body, and whether it shows any signs of activity.

  Recruiting at 2 sites Phase 1 DEM BioPharma, Inc. · Birtinya, Queensland and 1 other locations · NCT07805369

• Rectal cancer registry to track real-world treatments and outcomes

  This registry collects real-world data on how locally advanced rectal cancer is treated in Austria, to see how TNT and dMMR/MSI-H cases are managed and what outcomes occur.

  Recruiting at 2 sites Austrian Breast & Colorectal Cancer Study Group · Wiener Neustadt, Lower Austria and 5 other locations · NCT07780305

• YL201 plus serplulimab vs the usual chemo combo as first treatment for extensive-stage small cell lung cancer

  This trial tests whether adding YL201 to serplulimab can improve outcomes compared with standard carboplatin and etoposide plus serplulimab in adults with treatment-naïve extensive-stage SCLC.

  Recruiting at 2 sites Phase 3 MediLink Therapeutics (Suzhou) Co., Ltd. · Guangzhou, Guangdong and 1 other locations · NCT07739758

• Aerobic exercise and guided imagery for bowel problems after rectal cancer surgery

  This study tests whether a program of aerobic exercise plus guided imagery helps people with low anterior resection syndrome after rectal cancer surgery.

  Recruiting Biruni University · Istanbul · NCT07732894

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.